Physician profile
Stephen T Varner
NPI 1306883624
$1,364.19
in general payments reported to CMS, 2019-2025
24 companies · $556 in 2025
The $556 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $56.94 · 2021: $62.21 · 2022: $96.91 · 2023: $349 · 2024: $133 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847 · Travel and Lodging: $171 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.68 |
| Travel and Lodging | $171.47 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $376.15 | 2019-2025 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Coloplast Corp | $194.10 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $125.00 | 2023 | Exparel |
| Abbvie INC. | $109.63 | 2019-2022 | |
| Sage Therapeutics, LLC | $87.64 | 2019-2025 | Zurzuvae |
| Baxter Healthcare | $70.15 | 2024-2025 | Perclot |
| Bayer Healthcare Pharmaceuticals INC. | $58.62 | 2020-2025 | |
| Coopersurgical, INC. | $46.63 | 2019-2023 | Mara Console |
| Organon LLC | $31.38 | 2025 | Nexplanon |
| Meditrina | $30.01 | 2023-2024 | |
| Smith+Nephew, INC. | $23.52 | 2025 | Pico 14 |
| Sanofi Pasteur INC. | $22.78 | 2025 | |
| Kci USA, INC. | $21.42 | 2022 | |
| Pfizer INC. | $19.27 | 2023 | |
| Davol INC. | $18.78 | 2023 | Arista Ah Flexitip |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $18.60 | 2023 | Slynd |
| Duchesnay USA Incorporated | $16.64 | 2019 | |
| Supernus Pharmaceuticals, INC. | $16.58 | 2025 | Qelbree |
| Becton, Dickinson and Company | $14.83 | 2023 | Bd Onclarity |
| Millicent US INC | $13.36 | 2024 | Femring, Intrarosa |
| Evofem Biosciences, INC. | $13.04 | 2021 | |
| Ethicon US, LLC | $12.95 | 2021 | |
| Daiichi Sankyo INC. | $11.82 | 2020 | |
| Myovant Sciences INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Varner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.